Business · 24/10/20261 min read
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Summary
The source item contains limited metadata.
Original source language: PR Newswire — Global News ReleasesOpen original release →